Whitehawk Therapeutics' Antibody Drug Conjugates Indicate Potential Efficacy Against Cancer, Oppenheimer Says

robot
Abstract generation in progress

Oppenheimer suggests that Whitehawk Therapeutics’ antibody drug conjugates demonstrate potential effectiveness against cancer. The report also includes fourth-quarter financial results for Unity Software, showing a 35% year-over-year revenue increase to $609 million, although the company reported a quarterly loss of 66 cents per share. Further details on Whitehawk Therapeutics’ findings are limited in the provided snippet.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin